AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board
- Seasoned executive with extensive board experience across US and European biotechnology companies
- Brings extensive operational, strategic and transactional expertise as AstronauTx advances its innovative pipeline targeting improvements in sleep architecture to treat neurodegenerative diseases
London, UK, 7 January 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, today announces the appointment of Adam Rosenberg as Chair of its Board of Directors.
